Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Among patients undergoing percutaneous coronary intervention (PCI) with stents, the risk of cardiovascular complications after stopping dual antiplatelet therapy (DAPT) is highly variable depending on the context, and some patients experience no complications at all, according to the results of the Patterns of Non-Adherence to Anti-Platelet Regimens In Stented Patients (PARIS) study.
Amsterdam, The Netherlands, 1 September 2013 - Among patients undergoing percutaneous coronary intervention (PCI) with stents, the risk of cardiovascular complications after stopping dual antiplatelet therapy (DAPT) is highly variable depending on the context, and some patients experience no complications at all, according to the results of the Patterns of Non-Adherence to Anti-Platelet Regimens In Stented Patients (PARIS) study.“Our findings challenge existing paradigms for prolonging antiplatelet therapy in otherwise stable patients after PCI, and show that in a real-world setting physicians are making appropriate decisions in selecting low-risk patients for discontinuation,” said lead investigator Roxana Mehran, MD., Professor of Medicine and Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, New York.
“Conversely, when patients simply don’t comply or are forced off antiplatelet therapy because they are bleeding, their risk is significantly elevated,” she added.
The PARIS study, a prospective, international, multicenter, observational registry trial, enrolled more than 5-thousand patients with coronary artery disease undergoing PCI with stent implantation at 15 clinical sites in 5 countries between July, 2009 and December, 2010.Follow-up at 30 days, 6 months, 1 and 2 years determined whether patients had discontinued, interrupted or disrupted antiplatelet therapy and whether this resulted in any major adverse cardiovascular events (MACE).“Discontinuation” was defined as a physician-recommended cessation of medication for subjects believed to no longer need it, while “interruption” was defined as temporary (up to 14 days) due to surgical necessity, and “disruption” was due to bleeding or non-compliance. In a final analysis of 5,018 patients at 2, the study showed a cumulative incidence of discontinuation, interruption and disruption of 40.8%, 10.5% and 14.4%, respectively, while the cumulative incidence of MACE was 11.5%.At 1-year, which is the duration currently recommended for antiplatelet therapy, the cumulative incidence of discontinuation, interruption and disruption was 11.5%, 4.6% and 9.8% respectively, with a 7.4% cumulative incidence of MACE.The majority of MACE (74%) occurred in patients who had remained on their recommended antiplatelet therapy, but among those who had not, there was a 50% increased risk of MACE associated with disrupting compared to staying on medication, and a 37% decreased risk associated with discontinuation compared to staying on. In contrast, brief interruptions did not increase risk for thrombotic events such as stent thrombosis or myocardial infarction.
“The findings show that when physicians recommend discontinuation presumably because patients are stable, there is no risk of adverse events, but when patients simply don’t comply or are forced off antiplatelet therapy because they are bleeding, their risk is significantly elevated,” said Dr. Mehran.
For the latter group, a novel finding was that the risk of MACE was highest in the first 7 days of disruption (when there was a 7-fold increase), after which it decreased.Importantly, the study also showed that sustained antiplatelet therapy was not associated with reduced thrombotic risk compared to recommended discontinuation – a finding that goes against common assumption.
“In fact, there was a slight, though statistically non-significant reduction in risk associated with recommended discontinuation, which contrasts with some previous studies that have suggested a potential protective effect with prolonged antiplatelet therapy,” she said.
The PARIS study results show that the effect of antiplatelet cessation on cardiovascular risk is “modest” – offering insight on this interaction in the modern era of post-PCI therapy.Previous studies have not included such a broad range of subjects and did not account for the context around antiplatelet cessation, said Dr. Mehran.
“We hope that these novel findings will spur initiatives to standardize and harmonize criteria for DAPT cessation, analogous to previous efforts used for myocardial infarction and bleeding.”
Funding:The PARIS study was supported by an investigator-initiated grant from Bristol Myers Squib/Sanofi-Aventis. Representatives of the funding agency were not directly involved in the collection, management, analysis, or interpretation of the data.Disclosures:Dr. Mehran reports Institutional Research Grant Support from The Medicines Company, Bristol-Myers Squibb/ Sanofi and Lilly/ Daichii Sankyo and Consulting fees from Abbott Vascular, Astra Zeneca, Boston Scientific, Covidien, Janssen (J+J), Regado Biosciences, Maya Medical, and Merck. Dr. Steg reports research grants (to INSERM U698) from Sanofi and Servier. Dr. Steg reports speaking or consulting fees from Ablynx, Amarin, Astellas, AstraZeneca, Bayer, Boehringer- Ingelheim, BMS, Daiichi-Sankyo-Lilly, GSK, Medtronic, Merck, Novartis, Otsuka, Pfizer, Roche, sanofi, Servier, The Medicines Company and stock holdings in Aterovax. Dr. Kini reports consulting fees from WebMD. Dr. Stuckey serves on the Medical Advisory Board and has received honoraria from Boston Scientific, Eli Lilly/ Diachii Sankyo. Dr. Cohen reports consulting income/speaking honoraria from Eli Lilly, Astra Zeneca, Medtronic, Abbott Vascular and institutional research grant support from Medtronic, Abbott Vascular, Boston Scientific, Eli Lilly, Astra Zeneca. Dr. Berger reports institutional research grants from Janssen, The Medicines Company, AstraZeneca, Eli Lilly/ Daichii Sankyo, Bristol Myers Squibb/ Sanofi and consulting fees from Janssen and Medicure. The authors report no conflicts of interest.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2013. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.More information on the ESC Press Conference page: Hot Line I: Late Breaking Trials on Thrombosis
About the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2013The ESC Congress is currently the world’s premier conference on the science, management and prevention of cardiovascular disease. The spotlight of this year's event is "The Heart Interacting with Systemic Organs". ESC Congress 2013 takes place from 31 August to 4 September at the RAI centre in Amsterdam, Netherlands. More information on ESC Congress 2013 contact the ESC Press Office.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved